All In Biotech

BLA 761127 · Revance Therapeutics, Inc.

Daxxify

Daxibotulinumtoxina-Lanm · Intramuscular, Subcutaneous · Acetylcholine Release Inhibitor; Neuromuscular Blocker

NovelOrphan

CDER novel approval, Sep 7, 2022: To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity

Last checked: Nov 20, 2026Latest source record: Aug 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 7, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,077

324 Phase 3, 72 recruiting

FAERS reports

5,969

5,181 serious, 1,844 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of all botulinum toxin products, including DAXXIFY, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, an unapproved use for DAXXIFY, but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms [see Warnings and Precautions (5.1) ]. WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete boxed warning. The effects of DAXXIFY and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with...

What it is approved for

From the label in effect Nov 4, 2026.

DAXXIFY is an acetylcholine release inhibitor and neuromuscular-blocking agent indicated for: Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients. ( 1.1 ) The treatment of cervical dystonia in adult patients. ( 1.2 ) 1.1 Glabellar Lines DAXXIFY is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. 1.2 Cervical Dystonia DAXXIFY is indicated for the treatment of cervical dystonia in adult patients.

Mechanism: DAXXIFY blocks neuromuscular transmission at the neuromuscular junction by inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein necessary for the successful docking and release of acetylcholine vesicles within nerve endings. Recovery of neurotransmission occurs gradually as the neuromuscular junction recovers from SNAP-25 cleavage and as new nerve endings are formed.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DAXXIFY · DAXIBOTULINUMTOXINA-LANM 0.1ML · INJECTABLE, INTRAMUSCULAR, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Daxibotulinumtoxina" as an intervention, any sponsor and status, largest first.

All 1,077 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,430
  • drug ineffective1,941
  • drug intolerance1,370
  • product use in unapproved indication1,345
  • headache1,188
  • migraine1,122
  • nausea1,111
  • hypoaesthesia1,018
  • maternal exposure during pregnancy981
  • pain962
  • hypertension934
  • dizziness916

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20057
20062
20073
200831
200946
201042
201194
2012562
201313
201411
201512
201616
201724
201855
2019138
2020229
2021470
2022491
2023560
20241,059
20251,340
2026758

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Revance Therapeutics, Inc.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.